

1 **Physically acting products for head lice – the end of the** 2 **beginning**

3
4 Ian F Burgess

5
6 Medical Entomology Centre, Insect Research & Development Limited, Cambridge, UK

7
8 Corresponding Author:

9 Ian F Burgess

10 6 Quy Court, Colliers Lane, Stow-cum-Quy, Cambridge, Cambridgeshire, CB25 9AU, United
11 Kingdom

12
13 Email address: ian@insectresearch.com

14 15 **Abstract**

16 Treatment of head louse infestation has evolved from widespread use of neurotoxic insecticides
17 that have been extensively affected by resistance since the mid-1990s into the use of so-called
18 physically acting treatments. It is widely believed that physically acting products are effectively
19 “resistance proofed” because they do not act to inhibit any particular physiological mechanism
20 and most have some kind of occlusive effect on the target organism. Over the past 20 years
21 various new active materials have been utilized ranging from natural oils, synthetic oils, through
22 to surfactants both as excipients and active substances. Relatively few of these products have
23 been adequately tested clinically and, of those that have, there is now some indication that they
24 are less effective than when first introduced. The question therefore arises whether lice can
25 become resistant to these physically acting products. Only adequate testing both in the
26 laboratory and in clinical trials can determine their real effectiveness and claiming efficacy based
27 on the presence of a named chemical rather than demonstrated activity may result in acquired
28 resistance to these types of product also.

29

30

31

32

33

34 Introduction

35 Head lice with acquired resistance to pyrethroid insecticides were identified more or less
36 concurrently by several investigators from different countries in the early 1990s (Chosidow et
37 al., 1994; Mumcuoglu et al., 1995; Rupeš et al., 1995; Burgess et al., 1995). Subsequently
38 resistance and resistance mechanisms were identified in widely distributed territories (Picollo et
39 al., 1998; Pollack et al., 1999; Hunter & Barker, 2003; Kasai et al., 2009) and were also found to
40 affect other insecticides in addition to the pyrethroids (Downs et al., 1999, 2002; Kristensen et
41 al., 2006).

42 Despite repeated reports of treatment failure, and even attempts at litigation through class action
43 by frustrated consumers (Williams, McIntyre & Pilitere, 2001), most pediculicide manufacturers
44 failed to take positive action to address the problems, relying in some cases on historical data to
45 support efficacy (Vander Stichele, Dezeure & Bogaert, 1995); professional assessments that
46 suggested method or thoroughness of application technique influenced treatment outcome more
47 than physiological tolerance (Aston, Duggal & Simpson, 1998); or specific formulations that
48 showed better efficacy in some geographic regions (Bialek, Zelck & Fölster-Holst, 2011;
49 Bouvresse et al., 2012).

50 During the late 1990s, as resistance to various insecticides increased in intensity, many consumer
51 groups began to show a renewed interest in the use of natural materials for louse control,
52 although this was minimally reflected in scientific investigation (Mumcuoglu et al., 1996; Veal,
53 1996), and only more recently have researchers developed this interest further, with a plethora of
54 studies of the pediculicidal activity of plant extracts, essential oils, and other materials of plant
55 origin. In most cases, the underlying thought process has been that plant extracts of any kind are
56 sufficiently complex that any successful treatment would be less likely to be affected by
57 resistance; that naturally derived materials are potentially safer than synthetic neurotoxic
58 insecticides; and that they are environmentally more acceptable because they are biodegradable
59 with minimal if any environmental accumulation. In reality most of these factors have not been
60 tested fully, either experimentally or clinically, and reviews of the naturally derived treatment
61 prospects show a diverse and extensive range of preliminary investigations but few actual
62 products that have been properly evaluated and brought to market (Heukelbach, Speare &
63 Canyon, 2007; Heukelbach, Canyon & Speare, 2007). In many cases claims are made that plant
64 derived products act against insects by physical rather than physiological mechanisms. While
65 that concept can feasibly apply to fixed plant oils, such as unrefined coconut oil or pressed olive
66 oil, the majority of plant extracts operate through physiological mechanisms. For example, Tea
67 tree oil, a popular essential oil distillate from *Melaleuca alternifolia* used against lice (Barker &
68 Altman, 2010), like most mixtures of monoterpenes and terpene esters, can exert a solvent effect
69 on insect lipids but the major active components, terpinen-4-ol and 1,8-cineol the latter of which
70 is also the main constituent of eucalyptus oil, are both neurotoxins acting as acetylcholinesterase
71 inhibitors in a similar manner to the mode of action of organophosphorus insecticides (Ryan &

72 Byrne, 1988; Mills et al., 2004; Miyazawa & Yamafuji, 2005; Jankowska et al., 2018).
73 Therefore, contrary to the perceived ideas about these natural materials that they are not affected
74 by resistance, it is quite possible that a cross-resistance between essential oil components and
75 synthetic insecticides could result that not only renders the natural materials ineffective but also
76 enhances levels of resistance by selection of more tolerant insects capable of detoxifying both
77 groups of chemicals.

78 Consequently, only truly physically acting treatments could be considered not to be affected by
79 the resistance mechanisms to conventional insecticides. The first breakthrough alternative
80 therapeutic agents not relying on physiological mechanisms were actually based on technologies
81 that had been investigated, but never used, from the early 1980s. These products with a siloxane
82 (silicone) base proved to be highly effective in clinical studies in areas where resistance to
83 insecticides was prevalent and overall were significantly more effective than conventional
84 insecticide-based products (Burgess, Brown & Lee, 2005; Burgess, Lee & Matlock, 2007;
85 Burgess, Lee & Brown, 2008; Heukelbach et al., 2008), showing that these products were not
86 affected by the physiological resistance mechanisms affecting insecticides. Further studies
87 showed that these products exerted a physical mode of action by coating the insects and
88 smothering them by “asphyxiation” (Richling & Böckeler, 2008), prevention of water excretion
89 (Burgess, 2009), or else by disrupting cuticle lipid integrity resulting in dehydration (Barnett et
90 al., 2012). Each of these modes of action has been considered “resistance proof”, i.e. no known
91 mechanism of resistance was considered likely to affect the effectiveness of these types of
92 product and it was anticipated that there could be no pathway that would permit lice to develop
93 resistance to these types of technologies.

94 Although the two formulations first to market in this group of products based on siloxanes were
95 patent protected (Ansell, 2001; Campbell, Palma & Paulsen, 2003), this did not prevent the
96 development of a series of other alternative treatments based on siloxanes, mineral oils, and
97 synthetic oils, because the intellectual property was limited in its scope by prior art (Lover et al.,
98 1977) and newer or novel chemical entities were used in some cases (Boscamp, Hilscher &
99 Vater, 2007; Rossel, 2008; Panin, 2010). However, despite the fact that there are now probably
100 as many as 100 siloxane and synthetic oil-based products available worldwide, only a few have
101 ever been subjected to clinical evaluation and even fewer of these studies have been published in
102 peer reviewed journals (Burgess, Brown & Lee, 2005; Burgess, Lee & Matlock, 2007; Burgess,
103 Lee & Brown, 2008; Heukelbach et al., 2008; Kurt et al., 2009; Izri et al., 2010; Burgess &
104 Burgess, 2011; Burgess, Brunton & Burgess, 2013; Burgess, Burgess & Brunton, 2013; Wolf et
105 al., 2016).

106 In addition to synthetic oil-based materials, designed to coat lice and “smother” them, a number
107 of other materials have been investigated for activity that are believed to not directly affect
108 physiological processes. In some cases these include plant-derived fixed oils or derivatives of
109 these fixed oils, especially from coconut and neem. Neem oil is a complex mixture of

110 compounds, the principal components of which make it essentially similar to extra virgin olive
111 oil, but also including around 80 triterpenoids and similar compounds that putatively have some
112 pharmacologic function. None of these terpenoids is present at any great concentration and the
113 activity, if any, of the vast majority is unknown. Only azadirachtin, a highly oxidized
114 tetranortriterpenoid that has been demonstrated by those interested in plant protection to be an
115 antifeedant for caterpillars and other leaf eating insects, can be considered active. However, how
116 a large and complex molecule that primarily acts upon the function of the gut after ingestion
117 could act upon the biology of a blood feeding insect that draws its nutrition directly from its
118 host's circulatory system is difficult to reconcile. Nevertheless claims have been made for its
119 activity in an unspecified shampoo basis against head lice (Abdel-Ghaffar & Semmler, 2007;
120 Abdel-Ghaffar et al., 2012; Semmler et al., 2017). The product used has only been clinically
121 evaluated in rural communities in Egypt, where hair care products may be at a premium for the
122 population concerned, so it is possible that any modern surfactant based shampoo would have
123 exerted a similar effect to kill lice. Evidence from the UK suggests that neem itself has a low
124 activity against lice (Brown & Burgess, 2017) with a cure rate of just 6/24 (25.0%) following
125 four applications and a study performed in Thailand required not only a high concentration of
126 neem extract (6%), but also 16% eucalyptus oil in an alcoholic basis applied twice, in order to
127 achieve elimination of lice in 40/45 (88.9%) of those treated (Thawornchaisit et al., 2012).

128 In contrast to neem, coconut oil is rarely used in its original form but generally it is used as the
129 primary feedstock for a wide range of chemical entities used in the toiletry and cosmetic
130 industries, the majority of which are surfactants, wetting and spreading agents, or emollients.
131 Unfortunately this has resulted in considerable confusion over what if any activity coconut may
132 have against lice but, when it is considered that people in the tropical developing world have
133 used coconut oil as a hair conditioner treatment for centuries yet still have lice in their
134 communities, it makes it clear that coconut oil has little if any effect on lice. In contrast,
135 derivative surfactants may or do have some activity. This is quite variable depending upon the
136 chemical constituents of toiletry hair treatments used in any particular community and, just as
137 insecticides and essential oils used in low doses can select for lice capable of tolerating them,
138 lice exposed to low doses of surfactants and similar compounds can be selected for tolerance. A
139 good example was shown in a study of cocamide diethanolamine (cocamide DEA) lotion in
140 which *in vitro* screening using lice that had never been exposed to toiletry shampoos suggested
141 100% efficacy but when the product was used in community-based randomized clinical studies it
142 failed to achieve a cure rate better than 33.9% (19/56) irrespective of the dosing used (Burgess,
143 Brunton & Brown, 2015). Similarly, a study of a cocamide DEA-based shampoo, including
144 other coconut derived surfactants, performed in a different locality also produced a low treatment
145 success rate of 22/41 (53.7%) (Connolly et al., 2008). Theoretically this surfactant should be
146 effective to cause damage to the lipid waterproofing layer on the surface of lice, and this was
147 shown in the *in vitro* studies (Burgess, Brunton & Brown, 2015). However, since cocamide
148 DEA has been so widely used in toiletry shampoos and conditioners, many lice would have
149 experienced low dose exposures, which may have been increased after the popular rise of the

150 wet-combing with conditioner approach to treatment in which hair toiletry products are applied
151 to facilitate combing for quite long periods (around 30 minutes or so) on several occasions over a
152 two week period (Ibarra, 1996).

153 Other surfactant products have been shown to kill lice in a similar way by damage to the
154 waterproofing lipid coating of the lice (Burgess et al, 2014), but this activity was also influenced
155 by the formulation vehicle and less irritant, aqueous-based, preparations were less effective than
156 alcohol-based mixtures (Burgess et al, 2012), which suggests that surfactants alone have only a
157 limited capacity for disrupting cuticle lipids and require additional solvent action to facilitate the
158 activity. A similar lipid disruption effect is observable with a mixture of the fatty acid ester
159 isopropyl myristate and cyclomethicone (Barnett et al., 2012), which proved acceptably effective
160 (77.0%) during initial clinical studies (Burgess, Lee & Brown, 2008).

161 In North America there were no new products based on essentially similar physical modes of
162 action until 2017. Instead, the majority of new preparations have employed alternative
163 neurotoxins such as ivermectin (Pariser et al., 2012) and spinosad (Stough et al., 2009). One
164 product type sold in North America and Australia, based on the named active substance, 5%
165 benzyl alcohol, does claim to have a physical mode of action (Barker & Altman, 2010; Meinking
166 et al., 2010). However, the claim that the benzyl alcohol component of the product “*effectively*
167 *asphyxiates lice by ‘stunning’ the spiracles open, allowing the vehicle, comprising mineral oil*
168 *and other inactive ingredients, to infiltrate the ‘honeycomb’ respiratory apparatus and kill*
169 *lice*” (Meinking et al., 2010) is illogical and contrary to prior studies of louse anatomy. Webb
170 (1946) showed histologically that the spiracle is a highly sclerotized and immovable structure
171 and that the musculature controlling the opening of the neck of the trachea needs to contract,
172 rather than relax, in order to open the respiratory pathway. It is not possible to “stun” a muscle
173 into contraction. External stimuli cannot trigger contraction of the muscle unless a
174 pharmacological event occurs e.g. by inducing a tonic-clonic spasm or some similar neuro-
175 stimulatory effect. Additionally, the formulation of the 5% benzyl alcohol product (Ulesfia®
176 Lotion, Shionogi Inc., Florham Park, New Jersey, USA), is such that even if benzyl alcohol was
177 capable of having the claimed effect, the mineral oil is so effectively emulsified that it either
178 could not separate out and block the respiratory structures or would be washed away when the
179 product was rinsed off with water after just 10 minutes.

180 Interestingly, benzyl alcohol is listed as an excipient in some other products investigated for use
181 on the North American market. The currently available 0.9% spinosad product (Natroba™,
182 ParaPRO LLC, Carmel, Indiana, USA) contains 10% benzyl alcohol, making it difficult to work
183 out how it could possibly be considered an “inactive” component of the formulation. Similarly a
184 benzyl alcohol component has been reported as an excipient in an experimental treatment
185 containing 0.74% abametapir, which to date has not received its marketing approval from the
186 FDA but which proved effective in several clinical studies (Bowles et al., 2018).

187

188 **Current Trends**

189 After approximately 12 years of use, since the introduction of siloxanes and other lipids and lipid
190 emulsifying chemical products, what is the current level of effectiveness of these products in
191 clinical use? If the hypothesis were to hold true that the physical mode of action operates in such
192 a way that resistance is unlikely, or even not possible, then all of the products should remain as
193 efficacious as they were when first introduced. However, to eliminate entirely the possibility
194 that lice could acquire a tolerance for physically acting treatments is at best naïve and at worst
195 risky. Naïve in that it eliminates from thought the possibility that insects may either be selected
196 by these products for different physical and/or physiological characteristics that could help them
197 adapt to a the effects of the treatments and allow them to tolerate or avoid the active effects.
198 Risky in that, as was seen with continued reliance on neurotoxic insecticides long past the point
199 when they became ineffective, there could be a widespread failure to control the parasites.

200 *Evidence for resistance*

201 We have already considered the risks of cross-resistance between essential oils and neurotoxic
202 insecticides, or perhaps different mechanisms developing in parallel that can affect essential oils
203 as well as insecticides. In 1970 a product was formulated of 0.5% malathion in an alcoholic
204 basis that also contained approximately 12% of the essential oil terpenoids *d*-limonene and α -
205 terpineol. This product (Prioderm lotion, Napp Laboratories Ltd, Cambridge, UK), and a similar
206 competitor preparation (Suleo-M, Charwell Pharmaceuticals Ltd, Alton, UK), was sold in the
207 UK until 1988 when the original Prioderm was reformulated to remove the terpenoids to improve
208 the odor. Within a few weeks, complaints of failure were reported to health professionals and it
209 was later confirmed that the new preparation was less effective than the original because much of
210 the activity of the original was conferred by the terpenoids (Burgess, 1991). However, the Suleo
211 product as well as the Prioderm versions available in mainland Europe and the American
212 branded version (Ovide, Taro Pharmaceuticals USA, Inc., Hawthorne, NY, USA) retained the
213 terpenoids and the associated activity for considerably longer.

214 In 1999 the Suleo-M lotion product was used for a clinical study conducted in and around
215 Cambridge, UK (Burgess, Brunton & Brown, 2015) as a rescue treatment. Although lice in the
216 area were malathion resistant it was assumed the terpenoid content of the product would be
217 sufficient to effect a cure. It was subsequently found after several failed “rescue” attempts that
218 in some lice from failed treatments could be immersed in the fluid and survive. As a follow up
219 to investigate this further, and to confirm that insecticide resistant lice were susceptible to
220 silicone treatment, a group of head lice were collected families with long-term infestations and
221 then treated using two different malathion preparations in the laboratory. These treatments gave
222 similar results to those observed previously (Table 1) but all lice that survived the malathion

223 exposure were silicone susceptible. For the aqueous emulsion, the resistance was to malathion
 224 alone but failure of the alcoholic product with terpenoids indicated a parallel acquired resistance
 225 to the terpenoids.

226 Table 1. Survival of resistant head lice treated using different malathion preparations, one a
 227 simple aqueous emulsion and the other an alcoholic solution containing 12% terpenoids.
 228

Malathion product	Number of lice			Mortality %
	Total	Alive	Killed	
Aqueous	89	47	42	47.2
Alcohol/terpenoid	94	63	31	33.0
Control (water)	42	40	2	4.8

229

230 Although this observation confirmed that the lice were not affected by the neurotoxic activity of
 231 the terpenoids it also indicated that they were not affected by any solvent activity of the
 232 terpenoids on cuticle lipids. If that were the case it also raises a question as to whether other
 233 solvents or emulsifiers used to disrupt the protective lipid coating of the louse cuticle could be
 234 similarly affected by acquired tolerance.

235 Some similar effect appears to be happening with physically acting materials, for example,
 236 apparent loss of sensitivity appears to have developed to the isopropyl myristate/cyclomethicone
 237 (IPM/C) mixture, indicated by the differences between studies conducted a few years apart
 238 (Burgess, Lee & Brown, 2008; Burgess et al., 2017). In the first UK clinical investigations of the
 239 isopropyl myristate/cyclomethicone 50:50 mixture in 2005/6, it showed a consistent 77% cure
 240 rate (no lice found after the second application of treatment) in two related trials with 27/35 and
 241 57/74 participants cured (Burgess, Lee & Brown, 2008). Around 18 months later a different
 242 comparative trial found a non-significantly ($p = 0.25$) lower rate of 68% with 36/53 participants
 243 louse free after two treatments (Burgess et al., 2017). However, since then achieving successful
 244 treatments with this and other lipid-based products appears to be getting more difficult, with
 245 repeated individual cases reporting failure to eliminate infestation, irrespective of the
 246 formulations used, and recently an IPM-based preparation showed a clinical success rate of only
 247 41% (unpublished observations).

248 Was this difference between studies part of a continuing process of loss of effectiveness or the
 249 type of random observational variation that could occur in comparing any two clinical studies?
 250 If it was a loss of activity would it be confined to just that product or active material or would it
 251 affect other and different formulations and dosage forms in the same way as tolerance of
 252 pesticides? Few products use isopropyl myristate (IPM) as a named active substance for use

253 against lice, although it is much more widely used in toiletry products at low levels. One product
 254 that does name IPM as the named active substance in Europe is a pressurized isopropanol-based
 255 mousse (Vamousse™, Tyratch Inc., Morrisville, NC, USA). However, according to the USA
 256 documentation for the same product, IPM is an “inactive” ingredient and the product is sold as
 257 an unregistered homeopathic with the named active ingredient as “natrium muricatum 2x HPUS”
 258 (sodium chloride 1%). There is also a shampoo with the same ingredients plus 1% (2x HPUS)
 259 *Eucalyptus globulus* (presumably the oil). It only takes a few seconds thought to realize that 1%
 260 saline cannot eliminate lice; otherwise every child who swam in the sea (approximately 3.5%
 261 salts) would be louse free. Given the apparent “weasel words” surrounding these claimed active
 262 substances, how effective is the product? To date the evidence for these products has been
 263 limited to a white paper produced for the manufacturer (Krader, 2017) that only cites evidence
 264 from treating six (6) head lice and a larger number of insecticide susceptible laboratory reared
 265 body lice; and consumer reviews online suggest there is considerable geographic variability in
 266 success (Amazon, 2018). It is possible to see how IPM in an alcohol-based mousse might work
 267 against lice because these compounds are skin penetration enhancers that are just as likely
 268 effective on insect cuticle as on skin (Lane 2013). However, *ex vivo* tests following the pack
 269 instructions performed on freshly collected UK head lice (Table 2) suggested the bioavailability
 270 of the active material, whatever it is, is insufficient to kill head lice even 18 hours after treatment.

271 Table 2. Effect of Vamousse™ products on head lice recorded 18 hours after treatment.
 272

Treatment	Number of lice			Mortality	
	Total	Alive	Moribund		Immobile
Mousse	15	10	3	2	33.3
Shampoo	20	20	0	0	0.0
Control	21	19	1	1	9.5

273
 274 If physically acting products with differences of formulation, but containing the same named
 275 materials, demonstrate considerably different effectiveness, in much the same way as was
 276 observed with pesticides (Burgess, 1991), how many other products may not be as effective as
 277 claimed? Many of these products, like the neem shampoo and two of the silicone-based products
 278 referred to earlier (Abdel-Ghaffar & Semmler, 2007; Abdel-Ghaffar et al., 2012; Semmler et al.,
 279 2017; Heukelbach et Al., 2009; Izri et al., 2010), have only been evaluated in developing
 280 countries where lice may never have encountered many of the product excipients that are
 281 supposedly inactive. These excipient chemicals possibly have no effect on lice in countries with
 282 developed economies because they are included in so many other hair care preparations at low

283 concentrations, so the lice have acquired a tolerance for them, but, when applied to chemically
284 naïve lice, they can exert just as much killing activity as the named “active” substance.

285 *Fixed and synthetic oils*

286 Non-volatile oils that consist of molecules with no likely pharmacological activity, primarily
287 glycerides of saturated and non-saturated fatty acids, as well as a range of synthetic and naturally
288 derived mineral oils, are all considered to be capable of coating lice and inducing some kind of
289 occlusive effect. The level of interaction with the physical structures of the insects and the
290 ability of the oils to create and maintain a thorough coating over the body surface depend upon
291 the viscosity, surface tension, and wetting angle of the fluid. Since lice are coated with a lipid
292 layer the wetting capacity of these oils is relatively improved compared with some types of
293 product but the ability of the oily fluid to remain in contact with the louse depends upon the flow
294 characteristics of the fluid and the van der Waals forces applying to the interaction between the
295 oil and the substrate, in this case the louse cuticle (Perez, Schäffer & Steiner, 2001).

296 It has been claimed that silicone-based oils are capable of entering the tracheae of lice, filling up
297 the tracheal tracts completely, and blocking off all possibility of gaseous transfer within
298 approximately 1-3.5 minutes (Richling & Böckeler, 2008), although other authors claiming
299 similar observations state this process is slower (Candy, et al., 2018). How any fluid,
300 irrespective of its surface tension or viscosity, could fill a closed-ended narrow capillary tube
301 like an insect trachea that is already filled with air and, at the terminal portions in the tissues, is
302 also filled with water (Wigglesworth, 1930) is impossible to conceive unless the tracheae and
303 tracheoles are evacuated by means of a vacuum (Wigglesworth 1950). Consequently, attempts
304 to repeat these experiments as described by Richling & Böckeler (2008) were not successful
305 (Burgess, 2009). The evidence from gallium ion beam milling scanning electron microscopy
306 (Burgess, 2009) suggested that penetration of silicone fluids actually progressed no further than
307 the constricted part of the trachea proximal to the spiracle described by Webb (1946).

308 There is no controversy about the fact that these oily materials block the openings of the louse
309 respiratory system. However, recent work has shown that the effect of blocking access to air
310 does not result in asphyxiation (Candy, et al., 2018) so disruption of water excretion appears to
311 be a primary effect (Burgess, 2009), with the addition of some damage to the insect’s cuticle
312 lipids resulting from the solvent action of the applied oily materials dissolving them so they are
313 emulsified as the treatment product is washed off (Barnett et al., 2012). Consequently, it is
314 widely believed, and promoted by the pharmaceutical manufacturers of these products, that
315 siloxanes, synthetic oils, and fatty acid ester-based products are effectively “resistance proofed”,
316 primarily because there is no easily predictable mechanism whereby lice would be able to
317 overcome the process of fluid flowing into the spiracles and blocking them.

318 As with many treatments, a certain “failure to cure” rate occurred in all but one of the clinical
319 studies of these types of head louse treatment that have so far been published (Burgess, Brown &

320 Lee, 2005; Burgess, Lee, & Matlock, 2007; Burgess, Lee & Brown, 2008; Heukelbach et al,
321 2008; Kurt et al., 2009; Izri et al., 2010; Burgess & Burgess 2011; Burgess, Brunton & Burgess,
322 2013; Burgess, Burgess & Brunton, 2013; Ihde et al., 2015; Wolf et al., 2016; Semmler et al,
323 2017; Burgess et al., 2017). Interpretation of failure has varied from study to study but in all
324 cases there were some participants who had lice that unequivocally failed to respond to
325 treatment. If failure to apply the product correctly, in sufficient quantity to cover the head/hair,
326 and other compliance issues are eliminated, the question arises as to how lice could have or
327 develop a tolerance of these treatments.

328 If dissolution of cuticular lipid is a primary aspect of mode of action of these types of product
329 (Barnett et al., 2012), as well as that of some surface active compounds like 1,2-octanediol
330 (Burgess et al., 2012, 2014), a selection process for lice that have a different range or proportion
331 of lipids, with different solubility characteristics from those affected by the current treatments,
332 would prove less susceptible. In the study of IPM/C four hydrocarbon compounds were
333 identified as constituting the main components of the cuticle lipid that were most dissolved by
334 the product but their exact chemical nature was not identified. In the 1,2-octanediol study three
335 major hydrocarbons: C25, C27, and C29, plus various low concentration analytes, were found to
336 be affected by the treatment. Both of these studies were conducted on more or less naïve
337 populations of lice on which the chemical had not been previously used. Over time, incomplete
338 treatment regimens would select for lice less affected by the solvent action in much the same
339 way as lice were selected by physiologically active insecticides in the past. That some lice have
340 been able to adapt to tolerate materials capable of dissolving cuticle lipids, such as those in
341 commercial “stripping” shampoos used by hairdressers to remove conditioning lipids from hair,
342 was shown by the trials of cocamide diethanolamine (cocamide DEA) preparations referred to
343 earlier (Burgess, Brunton & Brown, 2015; Connolly et al., 2008).

344 *Is it possible to test for resistance to physically acting materials?*

345 Testing insects for susceptibility to physiologically active chemical substances is relatively
346 straightforward with numerous published protocols and guidelines from the World Health
347 Organization and others. Even testing of formulated products is reasonably straightforward
348 because most preparations investigated only contain one potentially active substance with known
349 activity. In contrast, physically acting materials, by their very nature described above, rely on
350 occlusive effects of some kind and *in vitro* it is almost impossible to mimic the relatively low
351 level of contact with lice that occurs as these, often low viscosity, fluids are dispersed over and
352 along hair shafts. In the laboratory, testing usually involves complete immersion of the insects
353 or their eggs in the fluid for a relatively prolonged period of time without draining off excess
354 fluid. Such a prolonged contact ensures that any surface interaction to disrupt the integrity of the
355 lipid coat of the insects, or flow of the fluid into the openings of the spiracles, can proceed as
356 completely as possible. In contrast, when applied to the hairs on the head, there is a momentary
357 immersion of the insects followed by a “draining” effect as the fluid spreads out over the surface

358 of the scalp and hair so that, unless the preparation is relatively viscous, the surface of the insect
359 may only retain a thin film of fluid, if any at all, depending upon the wetting characteristics of
360 the product.

361 In view of the difficulty in assessing the true effect of some of the oil-based preparations that
362 coat the insect cuticle, an assessment of whether they are effective can only be made clinically.
363 How that should be done is also open to some question. Historically most of these products have
364 been assessed in efficacy studies, i.e. trials in which the treatments were applied by members of
365 the investigation team (Burgess, Brown & Lee, 2005; Burgess, Lee & Matlock, 2007; Burgess,
366 Lee & Brown, 2008; Heukelbach et al., 2008; Kurt et al., 2009; Izri et al., 2010; Burgess &
367 Burgess, 2011; Burgess, Brunton & Burgess, 2013; Burgess, Burgess & Brunton, 2013; Wolf et
368 al., 2016; Burgess et al, 2017). This should ensure a thorough dosage and coverage so that the
369 outcome is a potentially “true” reflection of the likely best outcome effect. In this category of
370 products, only one published study has so far been conducted as a pragmatic or effectiveness
371 study, in which the treatment was given to the care giver and applied by them rather than by an
372 investigator (Ihde et al., 2015) but it suffered from a high rate of exclusion from analysis 39/97
373 (40.2%) and also required extensive nit combing along with application of a viscous silicone, so
374 it is difficult to identify true effectiveness of the applied product. Of all these investigations, only
375 one has so far shown an efficacy outcome of 100% (Burgess & Burgess, 2011) and all other
376 studies with that product and other products have resulted in some level of failure to cure.
377 Whether that failure was due to reinfestation from contacts in the community or simply because
378 the product was not able to kill all insects and their eggs varied between products and
379 investigations. However, very few of these investigations gave a cure rate close to the ideal
380 proposed by Vander Stichele and colleagues (1995), “*Moreover, inspection of the figure [not*
381 *shown here] leads us to recommend that only products with an expected cure rate of over 90%*
382 *should be tested and that this should be done in trials with sufficient power to establish cure*
383 *rates with a lower confidence limit above 90%.” How such a high cure rate could be predicted is*
384 impossible to determine because, as outlined above, *in vitro/ex vivo* tests are no useful guideline
385 in many cases.

386

387 Discussion

388 Recent clinical observations and consumer reports both suggest that at least some of the
389 physically acting preparations are losing effectiveness. Just as with the neurotoxic insecticides in
390 the 1980s and 90s (Aston, Duggal & Simpson, 1998), this phenomenon is occurring slowly with
391 as yet no substantiation and can easily be written off as failure by care givers to adequately apply
392 the treatment. Certainly, this is a factor contributing to the effect, partly because some people
393 have become blasé about the efficacy of products, partly because they are trying to economize
394 when faced with repeated need to treat, and partly through lack of skill. However, those same

395 factors contributed to the development of acquired resistance to commonly used insecticides like
396 permethrin and malathion and, when the warning signs of consumer dissatisfaction 25-30 years
397 ago were not heeded, it resulted in complete loss of usefulness of the insecticides in most
398 territories and regions within a little over a decade (Chosidow et al., 1994; Mumcuoglu et al.,
399 1995; Rupeš et al., 1995; Burgess et al., 1995; Picollo et al., 1998; Pollack et al., 1999; Downs et
400 al., 1999, 2002; Hunter & Barker, 2003; Kristensen et al., 2006; Kasai et al., 2009).

401 Irrespective of how well products might perform when applied by investigators, how well would
402 they work when applied by consumers? We have seen an interesting metamorphosis of reporting
403 since the introduction of these products in about 2005, from complete satisfaction and more or
404 less every time cure through to repeated treatment failures. Of course, some of the products that
405 are reported as failing either have never been subjected to clinical investigations or else such
406 investigations have never been published but even those products that may have given acceptable
407 results in clinical investigations have been reported as failing repeatedly by caregivers. In some
408 cases this is definitely due to inadequate application of the treatment but some appear to be due
409 to survival of either lice or their eggs after having been thoroughly saturated.

410 Identifying a mechanism whereby lice could now survive a treatment to which their ancestors
411 were wholly susceptible is really quite difficult, especially if the perceived mode of action is one
412 of occlusion of some anatomical feature like blocking of spiracle openings. As shown by
413 histology (Webb, 1946), the spiracles of lice are sclerotized and rigid objects inhibiting the
414 ingress of fluids into the respiratory tract. Such structures do not change easily in response of
415 selection pressures and, in this sense, there is little or no true selection pressure as might be
416 found in relation to physiologically acting insecticides that stimulate production of degradative
417 enzymes even in susceptible insects. Inevitably some lice may encounter incorrectly applied
418 treatments, and some of those may survive, but there would be no physiological stimulus and no
419 “mutational” effect to change the spiracle structure. However, what may occur is the survival of
420 lice that happen to have spiracles that are physically smaller or that, within individual variation,
421 are structured slightly differently so that it is more difficult for the fluid to enter or persist
422 therein. These features could be formed by heritable traits so their offspring could be more
423 successful in surviving a more intense exposure to the same treatment.

424 Such an interpretation might be considered fanciful or wholly speculative but observations of
425 recently collected lice in the laboratory suggest otherwise. Two observations of louse behaviour
426 support this possibility.

427 The first was of lice immersed in water. It has long been reported that lice in water become
428 inactive and that when immersed in water the louse “..holds its breath, and continues to do so
429 until unconscious” (Maunder, 1983), and more recently it was demonstrated that lice immersed
430 for extended periods did not take water into their tracheae (Candy et al., 2018). However,

431 recently we have observed lice in water moving around for several minutes, unlike previously,
432 and climbing out from the water if a suitable substrate was available.

433 The second observation relates to lice exposed to silicone-based and other oily preparations that
434 coat the lice over the whole body surface. If the preparation was insufficiently viscous to result
435 in a superficial build-up on the louse cuticle the insects were not immobilised but continued to
436 walk around with no apparent ill effects with the result that the treatment failed and the lice
437 continued to feed and reproduce normally. Lice surviving in this way were observed to carry a
438 film of the treatment fluid on their surfaces and they were only killed by complete immersion in
439 the fluid, something that could not physically occur on a patient's head.

440 If head lice are being selected for greater tolerance of being soaked in oily fluids, action needs to
441 be taken now by pediculicide manufacturers, clinical investigators, and regulators to establish
442 which types of formulations and which "active" materials are losing their effect. The same
443 vigilance needs to be set in place in parallel to ensure that the alternative types of product, such
444 as the newer insecticide products used in the U.S.A., do not show signs of loss of activity also.
445 Resistance to ivermectin has been identified in Senegal in Africa (Diatta et al., 2016;
446 Amanzougaghene et al., 2018) and this could spread outside of the region through travel and
447 migration. Also, since several of the topical formulations of these newer insecticides also
448 contain what are effectively therapeutic levels of benzyl alcohol any loss of sensitivity to that
449 material could also result in loss of activity of products not listing it as an active substance.

450 We have already discovered that some surfactants like cocamide diethanolamine have lost much
451 of their effect (Burgess, Brunton & Brown, 2015), and it is likely that others such as 1,2-
452 octanediol could suffer the same fate because they are slow acting and this may give lice the
453 opportunity to avoid lipid dissolution effects. Selection pressures may result in selecting lice that
454 produce a different ratio or range of lipids that protect their cuticle from those that were
455 previously shown to be removed by the surfactants (Burgess et al., 2012). The same problem
456 applies to lipid dissolution effects from volatile and fluidly mobile silicones and synthetic oils
457 (Barnett et al., 2012), which may account for the diminishing effectiveness of those products that
458 contain isopropyl myristate (Burgess et al., 2017; and unpublished observations). If the synthetic
459 oils lose effect it will create a major problem in those territories where they are widely used.

460 Viscosity of the final preparation appears to be important to ensure a thorough and complete
461 covering of the louse. This not only helps to immobilize it physically, in much the same way as
462 other viscous materials such as reported for hair conditioners (Ibarra, 1996) but also ensures that
463 all vulnerable surfaces, such as spiracles and cuticle lipids, are coated and occluded.
464 Consequently, a gel-like product appears to offer the best covering effect for delivery of
465 whatever active principle is in the preparation. However, in the light of some recent
466 observations, further investigation of the real activity of many physically acting preparations is
467 necessary through properly constructed clinical trials. As with insecticide products in the past, it

468 is not satisfactory to perform a write across desktop exercise based on one or two chemical
469 entities that happen to be included in each preparation. Increasingly specific physical and
470 chemical aspects of each formulation appear to be critical in determining the effectiveness of the
471 products in the elimination of infestation, meaning that unless the products are adequately
472 evaluated before marketing commences not only may they fail to perform as claimed but may
473 also create longer term problems by initiating the development of acquired resistance through
474 selection of altered physical characteristics of the target insects.

475

476 **Conclusions**

477 Physically acting treatments for head lice have made a considerable positive impact on control
478 and management of insecticide resistant populations of lice. So much so, that they have virtually
479 ousted insecticide-based products from the market in several European and other countries.
480 However, the interpretation of the term “physically acting” is somewhat loose in some regulatory
481 jurisdictions so that some of the products making this claim may be just a sensitive to the risks of
482 acquired resistance as the insecticides that preceded them because there is alternative evidence
483 that the chemicals in questions have a physiological activity in addition to any physical effect.

484 Irrespective of the physical nature of the activity of a preparation, the idea that lice cannot
485 become resistant to it is a false concept. Insects have demonstrated an ability to develop
486 resistance to a wide range of killing measures over the past 100 years and there is no reason to
487 justify a belief that synthetic oils and other physically acting chemicals are exempt from this risk.
488 As with claims about fixed vegetable oils like coconut, which may kill lice in urban communities
489 in developed countries, these are only good for use against lice that have never encountered
490 them. Regular use of these oils result in sub-lethal encounters that can select for lice able to
491 tolerate the exposure because they have some difference of physical characteristics or
492 physiology, and the same may apply to synthetic oils just as much. Consequently, in order to
493 avoid problems in the future for the currently successful products, a greater degree of care and
494 thoroughness is required in their pre-marketing evaluation and consumer use.

495

496 **Literature search**

497 Databases searched include PubMed, Science Direct, Scopus, Cochrane, Google Scholar,
498 <https://worldwide.espacenet.com>, pthiraptera.info, as well as hand searching online,
499 <https://clinicaltrials.gov>, the ISRCTN registry, and my own collection of more than three
500 thousand electronic reprints and references, using terms including: head lice, pediculosis,
501 treatment, clinical trials, and more specific target terms such as “physically acting treatment” or,
502 “non-insecticide treatment”.

503

504 **References**

505

506 **Abdel-Ghaffar F, Al-Quraishy S, Al-Rasheid KA, Mehlhorn H. 2012** Efficacy of a single
507 treatment of head lice with a neem seed extract: an in vivo and in vitro study on nits and motile
508 stages. *Parasitology Research* **110**: 277–280, doi: 10.1007/s00436-011-2484-3.

509 **Abdel-Ghaffar F, Semmler M. 2007** Efficacy of neem seed extract shampoo on head lice of
510 naturally infected humans in Egypt. *Parasitology Research* **100**: 329–332, doi: 10.1007/s00436-
511 006-0264-2.

512 **Amanzougaghene N, Fenollar F, Diatta G, Sokhna C, Raoult D, Mediannikov O. 2018**
513 Mutations in GluCl associated with field ivermectin-resistant head lice from Senegal.
514 *International Journal of Antimicrobial Agents* in press, doi: 10.1016/j.ijantimicag.2018.07.005.

515 **Amazon.co.uk. 2018** Vamousse 160 ml Head Lice Treatment Mousse. Available online:
516 <https://www.amazon.co.uk/Vamousse-Head-Lice-Treatment-Mousse/dp/B00MW5BN7U>
517 (accessed on 28th November 2018).

518 **Ansell J. 2001** *Method and composition for the control of arthropods*. International patent, WO
519 01/19190 A1, 22 March 2001.

520 **Aston R, Duggal H, Simpson J. (The Stafford Group). 1998** *Head Lice*: a report for
521 Consultants in Communicable Disease Control (CCDCs), The Stafford Document. Public Health
522 Medicine Environment Group: London, United Kingdom.

523 **Barker SC, Altman PM. 2010** A randomised, assessor blind, parallel group comparative
524 efficacy trial of three products for the treatment of head lice in children - melaleuca oil and
525 lavender oil, pyrethrins and piperonyl butoxide, and a “suffocation” product. *BMC Dermatology*
526 **10**: 6, doi:10.1186/1471-5945-10-6.

527 **Barnett E, Palma KG, Clayton B, Ballard T. 2012** Effectiveness of isopropyl
528 myristate/syclomethicone D5 solution of removing cuticular hydrocarbons from human head lice
529 (*Pediculus humanus capitis*). *BMC Dermatology* **12**: 15, doi:10.1186/1471-5945-12-15.

530 **Bialek R, Zelck UE, Fölster-Holst R. 2011** Permethrin treatment of head lice with knockdown
531 resistance-like gene. *New England Journal of Medicine* **364**: 386-387, doi:
532 10.1056/NEJMc1007171.

533 **Boskamp M, Hilscher H, Vater T. 2007** *Composition for combating ectoparasites and their*
534 *ova*. United States patent, US 2007/0212382 A1, 13 September 2007.

535 **Bouvresse S, Berdjane Z, Durand R, Bouscaillou S, Izri A, Chosidow O. 2012** Permethrin
536 and malathion resistance in head lice: Results of *ex vivo* and molecular assays. *Journal of the*
537 *American Academy of Dermatology* **67**: 1143-1150, doi: 10.1016/j.jaad.2012.04.011

- 538 **Bowles VM, VanLuvanee LJ, Alsop H, Hazan L, Shepherd K, Sidgiddi S, Allenby K,**
539 **Ahveninen T, Hanegraaf S. 2018** Clinical studies evaluating abametapir lotion, 0.74%, for the
540 treatment of head louse infestation. *Pediatric Dermatology* **35**: 616–621, doi: 10.1111/pde.13612.
- 541 **Brown CM, Burgess IF. 2017** Can neem oil help eliminate lice? Randomised controlled trial
542 with and without louse combing. *Advances in Pediatric Research* **4**: 9, doi:
543 10.12715/apr.2017.4.9.
- 544 **Burgess I. 1991** Malathion lotions for head lice – a less reliable treatment than commonly
545 believed. *The Pharmaceutical Journal* **247**: 630-632.
- 546 **Burgess IF. 2009** The mode of action of dimeticone 4% lotion against head lice, *Pediculus*
547 *capitis*. *BMC Pharmacology* **9**: 3, doi:10.1186/1471-2210-9-3.
- 548 **Burgess IF, Brown CM, Lee PN. 2005** Treatment of head louse infestation with 4% dimeticone
549 lotion: randomised controlled equivalence trial. *British Medical Journal* **330** (7505): 1423-1425,
550 doi:10.1136/bmj.38497.506481.8F.
- 551 **Burgess IF, Brown CM, Peock S, Kaufman J. 1995** Head lice resistant to pyrethroid
552 insecticides in Britain. *British Medical Journal* **311**: 752, doi: 10.1136/bmj.311.7007.752.
- 553 **Burgess IF, Brunton ER, Brown CM. 2015** Laboratory and clinical trials of cocamide
554 diethanolamide lotion against head lice. *PeerJ* **3**: e1368, doi: 10.7717/peerj.1368.
- 555 **Burgess IF, Brunton ER, Burgess NA. 2013** Single application of 4% dimeticone liquid gel
556 versus two applications of 1% permethrin creme rinse for treatment of head louse infestation: a
557 randomised controlled trial. *BMC Dermatology* **13**: 5, doi: 10.1186/1471-5945-13-5.
- 558 **Burgess IF, Brunton ER, Burgess NA, Burgess MN. 2017** Neem-silicone lotion and
559 ultrasound nit comb: a randomised, controlled clinical trial treating head louse infestation.
560 *Biomedical Dermatology* **1**: 8, doi: 10.1186/s41702-017-0009-0.
- 561 **Burgess IF, Brunton ER, French R, Burgess NA. 2014** Prevention of head louse infestation: a
562 randomized, double-blind, cross-over study of a novel concept product, 1% 1,2-octanediol spray
563 versus placebo. *BMJ Open* **4**: e004634, doi: 10.1136/bmjopen-2013-004634.
- 564 **Burgess IF, Burgess NA. 2011** Dimeticone 4% liquid gel found to kill all lice and eggs with a
565 single 15 minute application. *BMC Research Notes* **4**: 15, doi: 10.1186/1756-0500-4-15.
- 566 **Burgess IF, Burgess NA, Brunton ER. 2103** Tocopheryl acetate 20% spray for elimination of
567 head louse infestation: a randomised controlled trial comparing with 1% permethrin creme rinse.
568 *BMC Pharmacology and Toxicology* **14**: 43, doi: 10.1186/2050-6511-14-43.
- 569 **Burgess IF, Lee PN, Brown CM. 2008** Randomised, controlled, parallel group clinical trials to
570 evaluate the efficacy of isopropyl myristate/cyclomethicone solution against head lice. *The*
571 *Pharmaceutical Journal* **280**: 371-375.

- 572 **Burgess IF, Lee PN, Kay K, Jones R, Brunton ER. 2012** 1,2-octanediol, a novel surfactant, for
573 treating head louse infestation: identification of activity, formulation, and randomised, controlled
574 trials. *PLoS ONE* **7(4)**: e35419, doi:10.1371/journal.pone.0035419.
- 575 **Burgess IF, Lee PN, Matlock G. 2007** Randomised, controlled, assessor blind trial comparing
576 4% dimeticone lotion with 0.5% malathion liquid for head louse infestation. *PLoS ONE* **2(11)**:
577 E1127 doi:10.1371/journal.pone.0001127.
- 578 **Campbell WR, Palma KG, Paulsen NE. 2003** *Methods and compositions for treating*
579 *ectoparasites infestation*. United States patent, US 2003/0202997 A1, 30 October 2003.
- 580 **Candy K, Brun S, Nicolas P, Durand R, Charrel RN, Izri A. 2018** Do drowning and anoxia
581 kill head lice? *Parasite* **25**: 8, doi: 10.1051/parasite/2018015.
- 582 **Chosidow O, Chastang C, Brue C, Bouvet E, Izri MA, Monteny N, Bastuji-Garin S,**
583 **Rousset JJ, Revuz J. 1994** Controlled study of malathion and *d*-phenothrin lotions for *Pediculus*
584 *humanus* var. *capitis*-infested schoolchildren. *Lancet* **344**: 1724–1727, doi: 10.1016/S0140-
585 6736(94)92884-3.
- 586 **Connolly M, Stafford KA, Coles GC, Kennedy CTC, Downs AMR. 2008** Control of head lice
587 with a coconut-derived emulsion shampoo. *Journal of the European Academy of Dermatology*
588 *and Venereology* **23**: 67-69, doi: 10.1111/j.1468-3083.2008.02829.x.
- 589 **Diatta G, Abat C, Sokhna C, Tissot-Dupont H, Rolain JM, Raoult D. 2016** Head lice
590 probably resistant to ivermectin recovered from two rural girls in Dielmo, a village in Sine-
591 Saloum, Senegal. *International Journal of Antimicrobial Agents* **47(6)**:501-502, doi:
592 10.1016/j.ijantimicag.2016.03.013
- 593 **Downs AMR, Stafford KA, Harvey I, Coles GC. 1999** Evidence for double resistance to
594 permethrin and malathion in head lice. *British Journal of Dermatology* **141**: 508–511, doi:
595 10.1046/j.1365-2133.2000.03515.x.
- 596 **Downs AM, Stafford KA, Hunt LP, Ravenscroft JC, Coles GC. 2002** Widespread insecticide
597 resistance in head lice to the over-the-counter pediculocides in England, and the emergence of
598 carbaryl resistance. *British Journal of Dermatology* **146**: 88-93, doi: 10.1046/j.1365-
599 2133.2002.04473.x.
- 600 **Gellatly KJ, Krim S, Palenchar DJ, Shepherd K, Yoon KS, Rhodes CJ, Lee SH, Clark JM.**
601 **2016** Expansion of the knockdown resistance frequency map for human head lice (Phthiraptera:
602 Pediculidae) in the United States using quantitative sequencing. *Journal of Medical Entomology*
603 **53(3)**: 653-659, doi: 10.1093/jme/tjw023.
- 604 **Heukelbach J, Canyon D, Speare R. 2007** The effect of natural products on head lice: In vitro
605 tests and clinical evidence. *Journal of Pediatric Infectious Disease* **2**: 67-76, doi: 10.1055/s-
606 0035-1557021.

- 607 **Heukelbach J, Polger D, Oliveira FA, Khakban A, Ariza L, Feldmeier H. 2008** A highly
608 efficacious pediculicide based on dimeticone: Randomized observer blinded comparative trial.
609 *BMC Infectious Diseases* **8**: 115, doi:10.1186/1471-2334-8-115.
- 610 **Heukelbach J, Speare R, Canyon D. 2007** Natural products and their application to the control
611 of head lice: An evidence-based review. In *Chemistry of Natural Products: Recent Trends &*
612 *Developments*, 1st ed.; Brahmachari, G.; Ed; Trivandrum, India: Research Signpost, pp. 277-302,
613 ISBN 81-308-0140-X.
- 614 **Hunter JA, Barker SC. 2003** Susceptibility of head lice (*Pediculus humanus capitis*) to
615 pediculicides in Australia. *Parasitology Research* **90**: 476-478, doi: 10.1007/s00436-003-0881-y.
- 616 **Ibarra J. 1996** The bug stops here. *Health Education* **96**: 7-12, doi:
617 10.1108/09654289610118992.
- 618 **Ihde ES, Boscamp JR, Loh JM, Rosen L. 2015** Safety and efficacy of a 100% dimethicone
619 pediculicide in school-age children. *BMC Pediatrics* **15**: 70, doi: 10.1186/s12887-015-0381-0.
- 620 **Izri A, Uzzan B, Gordon MS, Bouges-Michel C. 2010** Clinical efficacy and safety in head lice
621 infection by *Pediculus humanis capitis* De Geer (Anoplura: Pediculidae) of a capillary spray
622 containing a silicon-oil complex. *Parasite* **17**: 329-335, doi: 10.1051/parasite/2010174329.
- 623 **Jankowska M, Rogalska J, Wyszowska J, Stankiewicz M. 2018** Molecular targets for
624 components of essential oils in the insect nervous system - a review. *Molecules* **23**: 34, doi:
625 10.3390/molecules23010034.
- 626 **Kasai S, Ishii N, Natsuaki M, Fukutomi H, Komagata O, Kobayashi M, Tomita T. 2009**
627 Prevalence of *kdr*-like mutations associated with pyrethroid resistance in human head louse
628 populations in Japan. *Journal of Medical Entomology* **46**: 77-82, doi: 10.1603/033.046.0110.
- 629 **Krader CG. 2017** White Paper: Effective pediculosis management in the era of pesticide-
630 resistant lice. *Drug Topics*, April 14th 2017. Available online: [https://vamousselice.com/wp-](https://vamousselice.com/wp-content/uploads/2018/04/Effective-Pediculosis-Management-in-the-Era-of-Pesticide-Resistant-Lice.pdf)
631 [content/uploads/2018/04/Effective-Pediculosis-Management-in-the-Era-of-Pesticide-Resistant-](https://vamousselice.com/wp-content/uploads/2018/04/Effective-Pediculosis-Management-in-the-Era-of-Pesticide-Resistant-Lice.pdf)
632 [Lice.pdf](https://vamousselice.com/wp-content/uploads/2018/04/Effective-Pediculosis-Management-in-the-Era-of-Pesticide-Resistant-Lice.pdf) (Accessed 29th November 2018)
- 633 **Kristensen M, Knorr M, Rasmussen AM, Jespersen JB. 2006** Survey of permethrin and
634 malathion resistance in human head lice populations from Denmark. *Journal of Medical*
635 *Entomology* **43**: 533-538, doi: 10.1093/jmedent/43.3.533.
- 636 **Kurt Ö, Balcioglu IC, Burgess IF, Limoncu ME, Girginkardesler N, Tabak T, Muslu H,**
637 **Ermis O, Sahin MT, Bilac C, Kavur H, Ozbel Y. 2009** Treatment of head lice with
638 dimeticone 4% lotion: comparison of two formulations in a randomised controlled trial in rural
639 Turkey. *BMC Public Health* **9**: 441, doi:10.1186/1471-2458-9-441.

- 640 **Lane ME. 2013** Skin penetration enhancers. *International Journal of Pharmaceutics* **447**: 12-
641 21, doi: 10.1016/j.ijpharm.2013.02.040.
- 642 **Lover MJ, Singer AJ, Lynch DM, Rhodes WE III. 1977** *Use of siloxanes as ectoparasiticides.*
643 Great Britain patent, GB 1 604 853, 18 October 1977.
- 644 **Maunder JW. 1983** The appreciation of lice. *Proceedings of the Royal Institution of Great*
645 *Britain* **55**: 1-30.
- 646 **Meinking TL, Villar ME, Vicaria M, Eyerdam DH, Paquet D, Mertz-Rivera K, Rivera HF,**
647 **Hiriart J, Reyna S. 2010** The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia™): A
648 safe and effective topical treatment for head lice (pediculosis humanus capitis). *Pediatric*
649 *Dermatology* **27**: 19-24, doi: 10.1111/j.1525-1470.2009.01059.x.
- 650 **Mills C, Cleary BJ, Gilmer JF, Walsh JJ. 2004** Inhibition of acetylcholinesterase by Tea Tree
651 oil. *Journal of Pharmacy and Pharmacology* **56**: 375-379, doi: 10.1211/0022357022773.
- 652 **Miyazawa M, Yamafuji C. 2005** Inhibition of acetylcholinesterase activity by bicyclic
653 monoterpenoids. *Journal of Agricultural and Food Chemistry* **53**: 1765–1768, doi:
654 10.1021/jf040019b.
- 655 **Mumcuoglu KY, Galun R, Bach U, Miller J, Magdassi S. 1996** Repellency of essential oils
656 and their components to the human body louse, *Pediculus humanus humanus*. *Entomologia*
657 *Experimentalis et Applicata* **78**: 309-314, doi: 10.1111/j.1570-7458.1996.tb00795.x.
- 658 **Mumcuoglu KY, Hemingway J, Miller J, Ioffe-Uspensky I, Klaus S, Ben-Ishai F, Galun R.**
659 **1995** Permethrin resistance in the head louse *Pediculus capitis* from Israel. *Medical and*
660 *Veterinary Entomology* **9**: 427–432, doi: 10.1111/j.1365-2915.1995.tb00018.x.
- 661 **Panin G. 2010** *Use of vitamin E or derivatives thereof for the control of arthropods.*
662 International patent, WO 2010/031584 A2, 25 March 2010.
- 663 **Pariser DM, Meinking TL, Bell M, Ryan WG. 2012** Topical 0.5% ivermectin lotion for
664 treatment of head lice infestation. *New England Journal of Medicine* **367**: 1687-1693, doi:
665 0.1056/NEJMoa1200107.
- 666 **Perez E, Schäffer E, Steiner U. 2001** Spreading dynamics of polydimethylsiloxane drops:
667 Crossover from Laplace to van der Waals spreading. *Journal of Colloid and Interface Science*
668 **234**: 178-193, doi: 10.1006/jcis.2000.7292.
- 669 **Piccolo MI, Vassena CV, Casadio AA, Massimo J, Zerba EN. 1998** Laboratory studies of
670 susceptibility and resistance to insecticides in *Pediculus capitis* (Anoplura: Pediculidae). *Journal*
671 *of Medical Entomology* **35**: 814–817, doi: 10.1093/jmedent/35.5.814.
- 672 **Pollack RJ, Kiszewski A, Armstrong P, Hahn C, Wolfe N, Abdul Rahman H, Laserson K,**
673 **Relford SR III, Spielman A. 1999** Differential permethrin susceptibility of head lice sampled in

- 674 the United States and Borneo. *Archives of Pediatric and Adolescent Medicine* **153**: 969–973, doi:
675 10.1001/archpedi.153.9.969.
- 676 **Richling I, Böckeler W. 2008** Lethal Effects of Treatment with a Special Dimeticone Formula
677 on Head Lice and House Crickets (Orthoptera, Ensifera: *Acheta domestica* and Anoplura,
678 Phthiraptera: *Pediculus humanus*). *Arzneimittelforschung* **58**: 248-254,
- 679 **Rossel B. 2008** *Foamable composition for killing arthropods and uses thereof*. International
680 patent, WO 2008/087148 A3, 24 July 2008.
- 681 **Rupeš V, Moravec J, Chmela J, Ledvinka J, Zelenková J. 1995** A resistance of head lice
682 (*Pediculus capitis*) to permethrin in Czech Republic. *Central European Journal of Public Health*
683 **3**: 30–32, doi: 10.21101/cejph.
- 684 **Ryan MF, Byrne O. 1988** Plant-insect coevolution and inhibition of acetylcholinesterase.
685 *Journal of Chemical Ecology* **14**: 1965–1975, doi: 10.1007/BF01013489.
- 686 **Semmler M, Abdel-Gaffar F, Gestmann F, Abdel-Aty M, Rizk I, Al-Quraishy S,**
687 **Lehmacher W, Hoff N-P. 2017** Randomized, investigator-blinded, controlled clinical study
688 with lice shampoo (Licener®) versus dimethicone (Jacutin® Pedicul fluid) for the treatment of
689 infestation with head lice. *Parasitology Research* **116**: 1863-1870, doi: 10.1007/s00436-017-
690 5461-7.
- 691 **Stough D, Shellabarger S, Quiring J, Gabrielsen AA, Jr. 2009** Efficacy and safety of
692 spinosad and permethrin crème rinses for pediculosis capitis (head lice). *Pediatrics* **124**: e389-
693 95, doi: 10.1542/peds.2008-3762.
- 694 **Thawornchaisit P, Amornsak W, Mahannop P, Buddhirakkul P, Pandii W, Connellan P,**
695 **Thompson D, Brushett D, Morris C. 2012** Combined neem oil 6% w/w and eucalyptus oil 16%
696 w/w lotion for treating head lice: *In vitro* and *in vivo* efficacy studies. *Journal of Pharmacy*
697 *Practice and Research* **42**: 189-192, doi: 10.1002/j.2055-2335.2012.tb00167.x.
- 698 **Vander Stichele R, Dezeure EM, Bogaert MG. 1995** Systematic review of clinical efficacy of
699 topical treatments for head lice. *British Medical Journal* **311**: 604–608, doi:
700 10.1136/bmj.311.7005.604.
- 701 **Veal L. 1996** The potential effectiveness of essential oils as a treatment for headlice, *Pediculus*
702 *humanus capitis*. *Complementary Therapies in Nursing and Midwifery* **2**: 97-101, doi:
703 10.1016/S1353-6117(96)80083-7.
- 704 **Webb JE. 1946** Spiracle structure as a guide to the phylogenetic relationships of the Anoplura
705 (biting and sucking lice), with notes on the affinities of the mammalian hosts. *Proceedings of the*
706 *Zoological Society of London* **116**: 49-119, doi: 10.1111/j.1096-3642.1946.tb00109.x.
- 707 **Wigglesworth VB. 1930** A theory of tracheal respiration in insects. *Proceedings of the Royal*
708 *Society London Series B* **106**: 229-250.

- 709 **Wigglesworth VB. 1950** A new method for injecting the tracheae and tracheoles of insects.
710 *Quarterly Journal of Microscopical Science* **91**: 217-224.
- 711 **Williams D, Chana McIntyre, and Chad Pilitere** vs Warner-Lambert Consumer Healthcare,
712 N.K.A. Pfizer, Inc., Bayer Corporation, Del Pharmaceutical, Inc., Del Laboratories, Inc. and
713 Care Technologies, Inc. Cause No. B010023-C, Orange County, Texas. **2001** Available online:
714 http://www.oocities.org/headlicehelper/OTC_Lice_Treatment_Lawsuit.html (accessed 28th
715 November 2018).
- 716 **Wolf L, Eertmans F, Wolf D, Rossel B, Adriaens E. 2016** Efficacy and safety of a mineral oil-
717 based head lice shampoo: A randomized, controlled, investigator-blinded, comparative study.
718 *PLoS ONE* **11(6)**: e0156853, doi: 10.1371/journal.pone.0156853.
- 719 **Yoon KS, Previte DJ, Hodgdon HE, Poole BC, Kwon DH, El-Ghar GEA, Lee SH, Clark**
720 **JM. 2014** Knockdown resistance allele frequencies in North American head louse (Anoplura:
721 Pediculidae) populations. *Journal of Medical Entomology* **51(2)**: 450-457, doi:
722 10.1603/ME13139.